Grünenthal Pharma GmbH & Co. KG; Gewisse Rechte und Vermögenswerte im Zusammenhang mit der Marke Crestor sowie deren Zweitmarken Provisacor, Simestat, Crestastatin, Visacor

On 01.12.2020 the following merger was notified at the Federal Competition Authority:

Planned purchase process

Grünenthal Pharma GmbH & Co. KG, Germany, intends to acquire through its wholly owned subsidiary, Grünenthal GmbH, Germany, certain rights and assets associated with the brand CRESTORTM and associated second brands (ProvisacorTM, 
SimestatTM, CrestastatinTM and VisacorTM) from IPR Pharmaceuticals, Inc., Puerto Rico, a wholly owned subsidiary of AstraZeneca PLC, United Kingdom.

The proposed transaction relates to the manufacture and distribution of pharmaceuticals. (ÖNACE-Code: C.21 – Production of pharmaceutical goods)

Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren

Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 29.12.2020.

Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.

Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.

back to list